Specifications TableSubject areaBiologyMore specific subject areaSerum proteomic analysis of obese people undergoing Laparoscopic gastric plication as a relatively new bariatric surgical technique.Type of dataRaw data, Tables and excel fileHow data was acquiredData was acquired by LC-MS/MS using a UPLC-nanoESI MS/MS setup with a NanoRSLC system (Dionex, CA, USA) coupled to a Q Exactive HF mass spectrometer (Thermo Scientific, Waltham, USA). The data was analyzed with MaxQuant (version 1.6.0.1).Data formatRaw and analyzed dataExperimental factorsHuman serum samples were analyzed pre-surgery and post-surgery. Initially, they were depleted of the six most abundant serum proteins.Experimental featuresLabel-free quantitative proteomics approach was used to analyze the serum samples. Proteins were digested using filter aided sample preparation. LC-MS/MS was used to analyze the purified peptides. The raw-files were analyzed with MaxQuant software (version 1.6.0.1) against the Uniprot human reference FASTA database (August 2017) and processed with Perseus version 1.6.0.2. Biological process and molecular function of differentially regulated proteins were determined using WebGestalt online tool. Meanwhile, their molecular networks were identified by IPA software.Data source locationLaboratory of Medical Mass Spectrometry, Department of Health Science and Technology, Aalborg University, Denmark.Data accessibilityData are available within this article and from ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository with the dataset identifier PXD010528.**Value of the data**•These data reveal the effect of laparoscopic gastric plication (LGP) on the proteome profile of obese people for the first time.•Data in this article provide information about the biological processes, molecular functions and molecular networks of differentially regulated proteins between pre- and post-surgery subjects.•These findings provide new insight into the underlying molecular mechanism associated with laparoscopic gastric plication that could be useful for further study in development of non-surgical weight loss strategies.

1. Data {#sec1}
=======

This report is associated with the research article aimed at investigating the effect of weight loss due to laparoscopic gastric plication (LGP) as a new bariatric surgical procedure on the human serum proteome [@bib1]. A total of 288 proteins was identified using a shotgun label-free proteomics experiment, of which 224 proteins were quantifiable with at least two unique peptides in 70% of samples or more ([Supplementary Table 1](#appsec1){ref-type="sec"}). The raw mass data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository [@bib2] with the dataset identifier PXD010528. The list of submitted proteomics raw-files into the ProteomeXchange and corresponding sample names are shown in [Table 1](#tbl1){ref-type="table"}. Significantly regulated proteins between pre- and post-surgery samples were discussed in detail in Savedoroudi et al. [@bib1]. Gene ontology enrichment analysis for biological process and molecular function of differentially regulated proteins at T1 and T2 are represented in [Table 2](#tbl2){ref-type="table"} and [Table 3](#tbl3){ref-type="table"}, respectively. In [Table 4](#tbl4){ref-type="table"}, molecular networks of differentially regulated proteins are shown.Table 1Description of file-names and MaxQuant output in the ProteomeXchange repository PXD010528. MS files were analyzed in MaxQuant. All samples were analyzed in triplicates. Timepoint 1: 1--2 months post-surgery; Timepoint 2: 4--5 months post-surgery.Table 1Raw fileSampleMS system2bef-12/Before surgeryQ Exactive HF2bef-22/Before surgeryQ Exactive HF2bef-32/Before surgeryQ Exactive HF2aft1-12/After surgery at timepoint 1Q Exactive HF2aft1-22/After surgery at timepoint 1Q Exactive HF2aft1-32/After surgery at timepoint 1Q Exactive HF3bef-13/Before surgeryQ Exactive HF3bef-23/Before surgeryQ Exactive HF3bef-33/Before surgeryQ Exactive HF3aft1-13/After surgery at timepoint 1Q Exactive HF3aft1-23/After surgery at timepoint 1Q Exactive HF3aft1-3_1707251018353/After surgery at timepoint 1Q Exactive HF3aft2-13/After surgery at timepoint 2Q Exactive HF3aft2-23/After surgery at timepoint 2Q Exactive HF3aft2-33/After surgery at timepoint 2Q Exactive HF4bef-14/Before surgeryQ Exactive HF4bef-24/Before surgeryQ Exactive HF4bef-34/Before surgeryQ Exactive HF4aft1-14/After surgery at timepoint 1Q Exactive HF4aft1-24/After surgery at timepoint 1Q Exactive HF4aft1-34/After surgery at timepoint 1Q Exactive HF5bef-15/Before surgeryQ Exactive HF5bef-25/Before surgeryQ Exactive HF5bef-35/Before surgeryQ Exactive HF5aft1-15/After surgery at timepoint 1Q Exactive HF5aft1-25/After surgery at timepoint 1Q Exactive HF5aft1-35/After surgery at timepoint 1Q Exactive HF5aft2-15/After surgery at timepoint 2Q Exactive HF5aft2-25/After surgery at timepoint 2Q Exactive HF5aft2-35/After surgery at timepoint 2Q Exactive HF6bef-16/Before surgeryQ Exactive HF6bef-26/Before surgeryQ Exactive HF6bef-36/Before surgeryQ Exactive HF6aft1-16/After surgery at timepoint 1Q Exactive HF6aft1-26/After surgery at timepoint 1Q Exactive HF6aft1-36/After surgery at timepoint 1Q Exactive HF6aft2-16/After surgery at timepoint 2Q Exactive HF6aft2-26/After surgery at timepoint 2Q Exactive HF6aft2-36/After surgery at timepoint 2Q Exactive HF7bef-17/Before surgeryQ Exactive HF7bef-27/Before surgeryQ Exactive HF7bef-37/Before surgeryQ Exactive HF7aft1-17/After surgery at timepoint 1Q Exactive HF7aft1-27/After surgery at timepoint 1Q Exactive HF7aft1-37/After surgery at timepoint 1Q Exactive HF7aft2-17/After surgery at timepoint 2Q Exactive HF7aft2-27/After surgery at timepoint 2Q Exactive HF7aft2-37/After surgery at timepoint 2Q Exactive HF8bef-18/Before surgeryQ Exactive HF8bef-28/Before surgeryQ Exactive HF8bef-38/Before surgeryQ Exactive HF8aft1-18/After surgery at timepoint 1Q Exactive HF8aft1-28/After surgery at timepoint 1Q Exactive HF8aft1-3_1707250858368/After surgery at timepoint 1Q Exactive HF8aft2-18/After surgery at timepoint 2Q Exactive HF8aft2-28/After surgery at timepoint 2Q Exactive HF8aft2-38/After surgery at timepoint 2Q Exactive HF9bef-19/Before surgeryQ Exactive HF9bef-29/Before surgeryQ Exactive HF9bef-39/Before surgeryQ Exactive HF9aft1-19/After surgery at timepoint 1Q Exactive HF9aft1-29/After surgery at timepoint 1Q Exactive HF9aft1-39/After surgery at timepoint 1Q Exactive HF10bef-110/Before surgeryQ Exactive HF10bef-210/Before surgeryQ Exactive HF10bef-310/Before surgeryQ Exactive HF10aft1-110/After surgery at timepoint 1Q Exactive HF10aft1-210/After surgery at timepoint 1Q Exactive HF10aft1-310/After surgery at timepoint 1Q Exactive HF10aft2-110/After surgery at timepoint 2Q Exactive HF10aft2-210/After surgery at timepoint 2Q Exactive HF10aft2-310/After surgery at timepoint 2Q Exactive HF11bef-111/Before surgeryQ Exactive HF11bef-211/Before surgeryQ Exactive HF11bef-311/Before surgeryQ Exactive HF11aft1-111/After surgery at timepoint 1Q Exactive HF11aft1-211/After surgery at timepoint 1Q Exactive HF11aft1-311/After surgery at timepoint 1Q Exactive HF11aft2-111/After surgery at timepoint 2Q Exactive HF11aft2-211/After surgery at timepoint 2Q Exactive HF11aft2-311/After surgery at timepoint 2Q Exactive HF12bef-112/Before surgeryQ Exactive HF12bef-212/Before surgeryQ Exactive HF12bef-312/Before surgeryQ Exactive HF12aft1-112/After surgery at timepoint 1Q Exactive HF12aft1-212/After surgery at timepoint 1Q Exactive HF12aft1-312/After surgery at timepoint 1Q Exactive HF14bef-114/Before surgeryQ Exactive HF14bef-214/Before surgeryQ Exactive HF14bef-314/Before surgeryQ Exactive HF14aft1-114/After surgery at timepoint 1Q Exactive HF14aft1-214/After surgery at timepoint 1Q Exactive HF14aft1-314/After surgery at timepoint 1Q Exactive HF14aft2-114/After surgery at timepoint 2Q Exactive HF14aft2-214/After surgery at timepoint 2Q Exactive HF14aft2-314/After surgery at timepoint 2Q Exactive HF15bef-115/Before surgeryQ Exactive HF15bef-215/Before surgeryQ Exactive HF15bef-315/Before surgeryQ Exactive HF15aft1-115/After surgery at timepoint 1Q Exactive HF15aft1-215/After surgery at timepoint 1Q Exactive HF15aft1-315/After surgery at timepoint 1Q Exactive HF17bef-117/Before surgeryQ Exactive HF17bef-217/Before surgeryQ Exactive HF17bef-317/Before surgeryQ Exactive HF17aft1-117/After surgery at timepoint 1Q Exactive HF17aft1-217/After surgery at timepoint 1Q Exactive HF17aft1-317/After surgery at timepoint 1Q Exactive HF17aft2-117/After surgery at timepoint 2Q Exactive HF17aft2-217/After surgery at timepoint 2Q Exactive HF17aft2-317/After surgery at timepoint 2Q Exactive HF18bef-118/Before surgeryQ Exactive HF18bef-218/Before surgeryQ Exactive HF18bef-318/Before surgeryQ Exactive HF18aft1-118/After surgery at timepoint 1Q Exactive HF18aft1-218/After surgery at timepoint 1Q Exactive HF18aft1-318/After surgery at timepoint 1Q Exactive HF21bef-121/Before surgeryQ Exactive HF21bef-221/Before surgeryQ Exactive HF21bef-321/Before surgeryQ Exactive HF21aft1-121/After surgery at timepoint 1Q Exactive HF21aft1-221/After surgery at timepoint 1Q Exactive HF21aft1-321/After surgery at timepoint 1Q Exactive HF**The MaxQuant output in folder \"txt\" contains a range of files containing important search information. Below file was used for further processing in Perseus post-analysis program and quantitative analysis.**proteinGroups.txtFile containing all proteins with corresponding label free quantitative informationTable 2Enrichment analysis of Gene ontology biological process and molecular function for differentially abundant proteins at T1, using WebGestalt online tool.Table 2Gen setDescriptionP-valueOverlap Gen-IDBiological ProcessGO:0051223regulation of protein transport4.87E-05CRP, GPLD1, APOA1, APOA2, APOD, IL1RAP, LCP1, SRGN, RBP4, SAA1, CD14, ADIPOQGO:0070201regulation of establishment of protein localization8.84E-05CRP, GPLD1, APOA1, APOA2, APOD, IL1RAP, LCP1, SRGN, RBP4, SAA1, CD14, ADIPOQGO:0034284response to monosaccharide0.000109GPLD1, APOA2, SERPINF1, APOM, SPARC, THBS1, ADIPOQGO:0032880regulation of protein localization0.000256CRP, GPLD1, APOA1, APOA2, APOD, IL1RAP, LCP1, SRGN, RBP4, SAA1, CD14, ADIPOQGO:0009743response to carbohydrate0.000315GPLD1, APOA2, SERPINF1, APOM, SPARC, THBS1, ADIPOQGO:0009746response to hexose0.000532GPLD1, APOA2, SERPINF1, APOM, THBS1, ADIPOQGO:0009749response to glucose0.000532GPLD1, APOA2, SERPINF1, APOM, THBS1, ADIPOQGO:0050707regulation of cytokine secretion0.000746CRP, APOA1, APOA2, IL1RAP, SRGN, SAA1, CD14GO:0051224negative regulation of protein transport0.00081APOA1, APOA2, APOD, SRGN, ADIPOQGO:1904950negative regulation of establishment of protein localization0.00081APOA1, APOA2, APOD, SRGN, ADIPOQMolecular FunctionGO:0005319lipid transporter activity0.00279APOF, APOA1, APOA2, APOD, APOM, RBP4GO:0005496steroid binding0.00279GC, APOF, APOA1, APOA2, APOD, SHBGGO:0071813lipoprotein particle binding0.0101CRP, APOA1, APOA2, THBS1GO:0071814protein-lipid complex binding0.0101CRP, APOA1, APOA2, THBS1GO:0043178alcohol binding0.0105APOF, APOA1, APOA2, APOD, RBP4GO:0008289lipid binding0.0122F10, GC, APOF, APOA1, APOA2, APOD, APOM, RBP4, SHBG, THBS1, CD14GO:0005215transporter activity0.0128GC, HBB, APOF, APOA1, APOA2, APOD, APOM, RBP4GO:0022892substrate-specific transporter activity0.0170HBB, APOF, APOA1, APOA2, APOD, APOM, RBP4GO:0015485cholesterol binding0.0206APOF, APOA1, APOA2, APODGO:0032934sterol binding0.0206APOF, APOA1, APOA2, APODTable 3Enrichment analysis of Gene ontology biological process and molecular function for differentially abundant proteins at T2, using WebGestalt online tool.Table 3Gen setDescriptionP-valueOverlap Gen-IDBiological ProcessGO:0010976positive regulation of neuron projection development0.000151FN1, IL1RAP, NRP1GO:0045666positive regulation of neuron differentiation0.000151FN1, IL1RAP, NRP1GO:0050769positive regulation of neurogenesis0.000151FN1, IL1RAP, NRP1GO:0051962positive regulation of nervous system development0.000151FN1, IL1RAP, NRP1GO:0010975regulation of neuron projection development0.000262FN1, IL1RAP, NRP1GO:0031346positive regulation of cell projection organization0.000416FN1, IL1RAP, NRP1GO:0045664regulation of neuron differentiation0.000416FN1, IL1RAP, NRP1GO:0050767regulation of neurogenesis0.000618FN1, IL1RAP, NRP1GO:0051960regulation of nervous system development0.000618FN1, IL1RAP, NRP1GO:0031344regulation of cell projection organization0.00119FN1, IL1RAP, NRP1Molecular FunctionGO:0004888transmembrane signaling receptor activity0.0226IL1RAP, NRP1GO:0099600transmembrane receptor activity0.0226IL1RAP, NRP1GO:0004872receptor activity0.0304PRG4, IL1RAP, NRP1GO:0060089molecular transducer activity0.0304PRG4, IL1RAP, NRP1GO:0038023signaling receptor activity0.0336IL1RAP, NRP1GO:0004871signal transducer activity0.0533IL1RAP, NRP1GO:0016301kinase activity0.135NRP1GO:0016504peptidase activator activity0.135FN1GO:0016772transferase activity, transferring phosphorus-containing groups0.135NRP1GO:0016773phosphotransferase activity, alcohol group as acceptor0.135NRP1Table 4Networks identified using IPA.Table 4Top Diseases and FunctionsScoreFocus MoleculesMolecules in NetworkT1Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry4519Adipokine, ADIPOQ, APCS, APOA1, APOA2, APOA4, APOD, APOF, APOM, C1q, C4BP, C4BPA, Collagen type II, CRP, ERK1/2, F10, Fibrinogen, GC, GPLD1, Growth hormone, HDL, HDL-cholesterol, Histone h4, IL12 (complex), LDL, NADPH oxidase, Pro-inflammatory Cytokine, RARRES2, Rbp, RBP4, SAA1, SERPINF1, SERPINF2, Sod, TTRCardiovascular System Development and Function, Cellular Movement, Cell-To-Cell Signaling and Interaction2813Akt, Ap1, collagen, Collagen Alpha1, Collagen type I, Collagen type IV, Collagen type VI, Collagen(s), DBH, DSG2, elastase, Fc gamma receptor, GP1BA, Gp2b3a Receptor, IL1, IL-1R, IL1RAP, Integrin, Iti, ITIH2, ITIH3, Laminin (complex), LCP1, Mek, Mmp, MMP9, p85 (pik3r), Pdgf (complex), PDGF BB, PEPD, SPARC, SRGN, Tgf beta, THBS1, VWFCellular Assembly and Organization, Nervous System Development and Function, Cell-To-Cell Signaling and Interaction189CD14, CFP, Cg, Creb, CRTAC1, ERK, estrogen receptor, F7, FAH, GOT, HBB, HISTONE, Histone h3, Ifn, IFN Beta, Ige, IgG, IgG1, IL12 (family), Immunoglobulin, Insulin, Mapk, NFkB (complex), NRP1, P38 MAPK, PI3K (complex), Pka, PRG4, Rac, RNA polymerase II, SHBG, SRC (family), TCF, Tnf (family), VegfCell-To-Cell Signaling and Interaction, Hematological System Development and Function, Immune Cell Trafficking158ACTG2, Actin, APCS, APP, C7, CASP8, caspase, CCL17, CD3, CFI, CLEC10A, CNDP1, CTF1, CYTIP, Ddx3x, DEFA6, Dstn/Dstnl1, FETUB, Granzyme, HBG1, IL13, IL10RB, Jnk, LIPA, LRP1, MMRN1, MT1G, PZP, Ras, S100A12, SCAVENGER receptor CLASS A, Sos, SRGN, TCR, ZFP36L1Inflammatory Response, Infectious Diseases, Inflammatory Disease53ADIPOR2, APCS, BBS12, CD163, CD276, CLEC10A, CMKLR1, coagulation factor, CYP19, CYTIP, estrone, FBXO42, Fcgr2, FSH, glycosylphosphatidylinositol, GPER1, GPR119, HFE, IL6, IL17B, IL1RL2, LPAR2, N-cor, NfkB1 RelA, PAX8, Proinsulin, RARRES2, S100A12, SCAVENGER receptor CLASS A, SCN9A, SELENOS, SHBG, SMPDL3A, Timp, TNF**T2**Cell-To-Cell Signaling and Interaction, Cell Death and Survival, Inflammatory Response217Akt, ANGPTL1, B4GALT5, C4BPB, CHST3, CLEC10A, Collagen type VI, CRP, Enolase, ERK, ERK1/2, EXT1, Fc gamma receptor, Fc receptor, FCER1A, FCN1, FN1, GFRA2, HS6ST1, IL1, IL6, IL1RAP, ITIH3, miR-191-5p (and other miRNAs w/seed AACGGAA), NFkB (complex), NfkB1-RelA, NRP1, PRG4, PRSS38, pyridoxamine, S100A12, SEMA3D, SHBG, Stat3-Stat3, TGFB1

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Study cohort and sample treatment {#sec2.1}
--------------------------------------

A total of 16 obese subjects undergoing LGP was investigated at three timepoints; pre-surgery (n = 16), at 1--2 months post-surgery (T1, n = 16), at 4--5 months post-surgery (T2, n = 9). The detailed characteristics of patients were mentioned in Savedoroudi et al. [@bib1]. The six most abundant serum proteins (albumin, IgG, IgA, antitrypsin, transferrin and haptoglobin) were depleted in the serum samples using the Agilent Multiple Affinity Removal column (4.6 × 50 mm) according to the instructions recommended by the manufacturers (Agilent Technologies, CA, USA). Then, the filter-aided sample preparation (FASP) protocol was utilized to prepare samples as described previously [@bib1], [@bib3]. Written consent was obtained from all participants and the institutional review board and the ethic committee of Shahid Beheshti University approved the study protocol for Human rights (IR.SBU.ICBS.97/1019).

2.2. LC-MS/MS analysis {#sec2.2}
----------------------

Initially, the peptides were resuspended in 2% acetonitrile, 0.1% FA and 0.1% trifluoroacetic acid. LC-MS/MS analysis was carried out on a UPLC-nanoESI MS/MS setup with a Dionex RSLC nanopump (Dionex, CA, USA). The system was coupled online with an emitter for nanospray ionization (New objective picotip 360-20-10) to a Q Exactive HF mass spectrometer (Thermo Scientific, Waltham, USA). The samples were analyzed in a random order, in triplicates. The peptide material was loaded onto a 2cm C18 trapping column (Dionex Acclaim PepMap RSLC C18) and separated using a 75cm C18 reversed-phase column (Dionex Acclaim PepMap RSLC C18). Both columns were kept at 60 °C. The peptides were eluted with a gradient of 98% solvent A (0.1% FA) and 2% solvent B (0.1% FA in acetonitrile), which was increased to 8% solvent B on a 5-min ramp gradient and subsequently to 30% solvent B on a 45-min ramp gradient, at a constant flow rate of 300nL/min. The mass spectrometer was operated in positive mode using a Top15 data-dependent MS/MS scan method. A full MS scan in the 375--1500 m/z range was acquired at a resolution of 120 000 with an AGC target of 3 × 10^6^ and a maximum injection time of 50 ms. Fragmentation of precursor ions was performed by higher-energy C-trap dissociation with a normalized collision energy of 27. MS/MS scans were acquired at a resolution of 15000 with an AGC target of 2 × 10^5^; maximum injection time was 100 ms. Dynamic exclusion was set to 5s.

2.3. Data analysis and processing {#sec2.3}
---------------------------------

Mass spectrometry data were analyzed in MaxQuant version 1.6.0.1 and searched against the Uniprot human reference FASTA database (August 2017) [@bib4], [@bib5]. Label-free protein quantitation (LFQ) algorithm was performed with a minimum ratio count of 1. Standard settings in MaxQuant were employed, including carbamidomethylation of cysteines as a fixed modification, and acetylation of protein N-terminals, oxidation of methionine, and deamidation of asparagine and glutamine as variable modifications. A maximum of two tryptic missed cleavages was allowed. The false discovery rate (FDR) of identified proteins and peptides was set to a maximum of 1%, using a target-decoy fragment spectra search strategy. Hereby, high confidence identifications were ensured. The "match between runs" feature was enabled to transfer peptide identifications across LC-MS/MS runs, based on accurate retention time and mass-to-charge. The output from MaxQuant, containing the list of proteins identified below 1% FDR, was further filtered and processed in Perseus version 1.6.0.2 [@bib6]. All reverse hits and proteins identified only by site were removed from further analysis, and the data were log 2-transformed. At least two unique peptides were required for a protein quantitation. Additionally, the unique peptides were required to be quantifiable in at least 70% of samples.

2.4. Bioinformatics analysis {#sec2.4}
----------------------------

Differentially regulated proteins between pre- and post-surgery subjects were functionally categorized based on gene ontology (GO) classification using WEB-based GEne SeT AnaLysis Toolkit (WebGestalt) [@bib7]. Identification of networks was performed with Ingenuity Pathway Analysis software (IPA; Ingenuity Systems, Redwood City, CA, [www.ingenuity.com](http://www.ingenuity.com){#intref0020}). Gene symbols and the corresponding protein fold change were imported to IPA software using core analysis. Standard settings in IPA were employed, including: direct and indirect relationships between focused molecules with default settings of 35 molecules/network, based on experimentally observed data (high confidence predictions and moderate confidence interactions excluded) were considered. All sources of data from human, mouse and rat studies in the Ingenuity Knowledge Base were included.
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